Metformin Market Report 2026

Metformin Market Overview

• Metformin market size has reached to $4.44 billion in 2025 • Expected to grow to $5.99 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: Increasing Prevalence Of Diabetes Driving Growth Of The Metformin Market • Market Trend: Innovative Triple-Drug Fixed-Dose Combinations For Diabetes Management • North America was the largest region in 2025.

What Is Covered Under Metformin Market?

Metformin is an oral medication primarily used to treat type 2 diabetes, belonging to the biguanides class. It works by decreasing glucose production in the liver, increasing insulin sensitivity to improve glucose uptake by muscles, and reducing glucose absorption from the intestines. The main types of metformin are standard-release tablets and slow-release tablets. Standard-release tablets are a type of metformin formulation where the active ingredient is released quickly after ingestion, providing rapid blood sugar control. The various dosage types include 500mg, 750mg, 850mg, and 1g used in various end-users such as clinics, hospitals, homecare, and other end-users.

What Is The Metformin Market Growth Forecast?

The metformin market size is expected to see strong growth in the next few years. It will grow to $5.99 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to rising demand for extended-release formulations, expansion of telemedicine diabetes care, integration with wearable glucose devices, increasing focus on combination therapies, growing health awareness campaigns. Major trends in the forecast period include precision medicine-based diabetes optimization, AI-driven treatment personalization, digital glucose monitoring integration, automated pharmaceutical manufacturing, iot-enabled prescription adherence tracking.

Global Metformin Market Segmentation

1) By Product Type: Standard-Release Tablets, Slow-Release Tablets 2) By Dosage Type: 500MG, 750MG, 850MG, 1G 3) By End-User: Clinics, Hospitals, Homecare, Other End-Users Subsegments: 1) By Standard-Release Tablets: 500 Mg, 850 Mg, 1000 Mg 2) By Slow-Release Tablets: 500 Mg, 750 Mg, 1000 Mg

What Is The Driver Of The Metformin Market?

The increasing prevalence of diabetes is expected to propel the growth of the metformin market going forward. Diabetes is a health issue that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it makes. The prevalence of diabetes is due to several factors, such as the obesity pandemic, genetic predispositions, lifestyle modifications, restricted access to healthcare, and exposure to particular toxins. Metformin assists in managing type 2 diabetes by lowering blood sugar, increasing weight loss, enhancing insulin sensitivity, and possibly providing other cardiovascular advantages. For instance, in February 2023, according to Diabetes Canada, a Canada-based non-profit organization, In Canada, the estimated prevalence of diabetes is projected to increase from 2,409,000 cases (15% of the population) in 2023 to 3,009,000 cases (17% of the population) by 2033. Therefore, the increasing prevalence of diabetes is driving the growth of the metformin industry.

Key Players In The Global Metformin Market

Major companies operating in the metformin market are Wockhardt Limited, Aarti Drugs, Abhilash Chemicals Private Limited, Farmhispania, Rochem International Inc., Chr. Olesen Group, Aspire Lifesciences Pvt. Ltd., Ria Lifesciences Pvt. Ltd., LGM Pharma, HRV Global Life Sciences, Octavius Pharma Pvt. Ltd., USV Private Limited, Zeon Pharma Industries India Pvt. Ltd., Atman Pharmaceuticals, Anwita Drugs & Chemicals Pvt. Ltd., IOL Chemicals and Pharmaceuticals, Granules India Limited, Angels Pharma India Private Limited, Auro Laboratories Ltd, Wanbury Ltd, Shouguang Fukang Pharmaceutical Co, Vistin Pharma ASA, Keyuan Pharmaceutical

Global Metformin Market Trends and Insights

Major companies operating in the metformin market are focusing on developing innovative diabetes medications, such as triple-drug FDC, to strengthen their position in the market. A triple-drug Fixed-Dose Combination (FDC) for diabetes medications typically refers to a single tablet or capsule combining three different antidiabetic medications. These combinations are designed to provide synergistic effects in managing blood sugar levels and improving overall glycemic control in patients with type 2 diabetes. For instance, in October 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical company, launched the first triple-drug fixed-dose combination (FDC) of teneligliptin with dapagliflozin and metformin in India. This FDC, branded as Zita DM, contains teneligliptin (20 mg), dapagliflozin (10 mg), and metformin SR (500 mg/1000 mg) in a fixed dose. It is designed to improve glycemic control in adult patients with Type 2 diabetes, particularly those whose diabetes is uncontrolled by metformin or who require the addition of teneligliptin and dapagliflozin as separate drugs.

What Are Latest Mergers And Acquisitions In The Metformin Market?

In April 2023, SK Capital Partners LP, a US-based investment firm, acquired Apotex Pharmaceutical Holdings Inc. for an undisclosed amount. With this acquisition, SK Capital aims to expand its footprint in the pharmaceutical industry, leveraging Apotex's extensive portfolio of generic medications, including metformin. Apotex Pharmaceutical Holdings Inc. is a Canada-based pharmaceutical company that manufactures metformin.

Regional Outlook

North America was the largest region in the metformin market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Metformin Market?

The metformin market consists of sales of glucophage, fortamet, glumetza, riomet, and linagliptin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Metformin Market Report 2026?

The metformin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the metformin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.